#### Title Page

1

- 2 Prevalence of class A ESBL class B and D carbapenemase
- 3 encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in
- 4 gram-negative bacterial pathogens isolated from various
- 5 clinical samples collected from northern region of United Arab
- 6 Emirates.
- 7 Premalatha Ragupathi<sup>1</sup>¶, Vaneezeh Khamisani<sup>1</sup>¶, Aisha Fadila Sadiq<sup>1</sup>¶, Mariam Aylu Mobiddo<sup>1</sup>¶,
- 8 Nazeerullah Rahamathullah<sup>1,2</sup>¶\*, Sovan Bagchi<sup>1</sup>, Ala Kamian<sup>1</sup>, Nasir Parwaiz<sup>3</sup>, Mohammad
- 9 Shahid Akhtar<sup>3</sup>
- 11 <sup>1</sup>Department of Biomedical Sciences, College of Medicine, Gulf Medical University, Ajman,
- 12 UAE.

10

- 13 <sup>2</sup>Thumbay Research Institute for Precision Medicine, College of Medicine, Gulf Medical
- 14 University, Ajman, UAE.
- <sup>3</sup>Thumbay Laboratory, Thumbay University Teaching Hospital, Gulf Medical University, Ajman,
- 16 UAE.
- 17 \*Corresponding author
- dr.nazeer@gmu.ac.ae (NR)
- 19 These authors contributed equally to this work

**Short Title:** Class A ESBL genes  $bla_{CTX-M}$ ,  $bla_{TEM}$ ,  $bla_{SHV}$  and class B & D carbapenemase

encoding genes  $bla_{NDM}$ ,  $bla_{IMP}$ ,  $bla_{OXA-48}$ .

### **Abstract**

20

21

22

23

25

26

27

29

30

31

32

33

34

35

36

## **Objective**

24 The aim of this study was to assess the prevalence of class A ESBL, class B and D carbapenemase

encoding genes ( $bla_{CTX-M}$ ,  $bla_{TEM}$ ,  $bla_{SHV}$ ,  $bla_{NDM}$ ,  $bla_{IMP}$  and  $bla_{OXA-48}$ ) in gram-negative bacterial

pathogens isolated from various clinical samples collected from northern region of UAE.

#### Methods

A laboratory based experimental study was conducted from October 14, 2021, to June 30, 2022.

A total of 3670 various clinical samples (urine, blood, pus, and sputum) were obtained from

patients attending the in and out-patient departments of Thumbay University Hospital and various

other hospitals of Northern Emirates of UAE, processed for routine bacterial culture examination

and determined their antibiotic sensitivity pattern especially ESBL and carbapenem resistance

using MicroScan Neg Breakpoint Combo 50 panel. Molecular detection of class A ESBL, class B

and D carbapenemase encoding genes ( $blac_{TX-M}$ ,  $bla_{TEM}$ ,  $bla_{SHV}$   $bla_{NDM}$ ,  $bla_{IMP}$  &  $bla_{OXA-48}$ ) were

performed on the ESBL and carbapenemase producing gram negative bacteria. Partial genomic

sequencing and phylogenetic tree analysis was performed on the most predominant ESBL gene

37  $bla_{CTX-M}$ .

### **Results**

In total, 1098 bacterial cultures were obtained, of which 833 were gram negative bacteria and among them, 209 (25.1%) were ESBL producers and 40 (4.8%) were both ESBL and carbapenemase producers. In all the 249 bacterial isolates, the ESBL and carbapenemase encoding genes ( $bla_{CTX-M}$ ,  $bla_{TEM}$ ,  $bla_{SHV}$ ,  $bla_{NDM}$  &  $bla_{IMP}$ ) were detected except  $bla_{OXA-48}$ . The  $bla_{CTX-M}$  (n=72) was the predominantly harbored gene followed by  $bla_{TEM}$  (n=56) and  $bla_{SHV}$  (n=29), mostly detected in E. coli (n=157), then K. pneumoniae (n=41), P. aeruginosa (n=18) & A. baumannii (n=7). The  $bla_{NDM}$  &  $bla_{IMP}$  were detected in K. pneumoniae (n=4), A. baumannii (n=3) and P. aeruginosa (n=2) for  $bla_{IMP}$ . The gene combinations such as  $bla_{CTX-M+TEM}$  (n=15),  $bla_{CTX-M+TEM}$ + $bla_{SHV}$  (n=6) were co-harbored in 36 E. coli and in the K. pneumoniae, the  $bla_{CTX-M+TEM}$  (n=15),  $bla_{CTX-M+SHV}$  (n=15),  $bla_{CTX-M+SHV}$  (n=15),  $bla_{TEM+SHV}$  (n=3),  $bla_{TEM+NDM}$  (n=1) were detected. The  $bla_{CTX-M+TEM}$ ,  $bla_{CTX-M+SHV}$  &  $bla_{CTX-M+TEM+SHV+IMP}$  were detected in one P. aeruginosa and in one A. baumannii, the  $bla_{TEM+NDM}$ ,  $bla_{TEM+NDM}$  &  $bla_{CTX-M+TEM+SHV+IMP}$  were detected.

## Conclusion

The highest bacterial culture positivity was detected in the urine samples. 25.1% of the Gram-ve bacteria were only ESBL producers and 4.8% were both the ESBL & carbapenemase producers. 44.5% of ESBL & carbapenemase producing bacteria harbored the *bla<sub>CTX-M</sub>* and mostly detected in the *E. coli*, then *K. pneumoniae* and *P. mirabilis*. Multiple gene combinations were detected in 5% *P. aeruginosa*, 10% *A. baumannii* and 3.82% *E. coli*. This finding highlights the importance of molecular detection of ESBL & carbapenemase producing genes to emphasize the monitor and control the development of multi drug resistant Gram-ve bacterial pathogens.

- **Keywords:** E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis, A. baumannii, Multidrug resistant,
- 60 ESBL genes, carbapenemase producing genes.

## Introduction

59

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Antibiotic-resistant bacterial infections are now a serious problem worldwide and have become a global threat to public health, animal production, and environmental health. Globally, more than 7 million people die every year from multidrug resistant bacterial infection. It is estimated that 10 million people will die from antimicrobial resistant (AMR) infections by 2050.[1, 2] Over prescribing antibiotics, irresponsible usage and not adhering to prescription are some of the leading causes of development of antibiotic resistance. [3, 4] Gram-negative bacteria are more prone to develop antibiotic resistance than other bacteria and due to the enhanced use of beta-lactam antibiotics, the bacterial pathogens have developed to produce the enzyme beta lactamase using plasmid which counteract the beta lactam compound. [5, 6] The rapid spread of antibiotic resistance genes among the gram-negative bacteria facilitated by the mobile genetic elements; plasmids and transposons are responsible for resistance towards a broad spectrum of antibiotics and have established the pivotal role in the dissemination of AMR.[7] Spreading of the plasmid mediated beta lactamase in gram negative bacterial pathogens is known as extended spectrum of beta lactamase (ESBL). Molecular classification of the β-lactamases divided into A, B, C, D enzymes [8, 9]. The class A enzyme producing genes are  $bla_{TEM}$ ,  $bla_{SHV}$ and  $bla_{CTX-M}[10]$ . The  $bla_{TEM}$  is commonly found in Gram-negative bacteria [11, 12] and the gene  $bla_{CTX-M}$  produces an enzyme called cefotaximase that inhibits the activity of the cefotaxime and as of March 2019, over 172 CTX-M types have been identified and described [13-15]. The gene

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

 $bla_{SHV}$  and  $bla_{TEM}$  are structurally similar and as of February 2018, over 223 TEM and 193 SHV types have been listed in public databases [16]. The ESBL producers have emerged as a major source of resistance among the gram-negative bacteria, more predominantly in the Escherichia coli and Klebsiella pneumoniae; thereby becoming a global concern. [17] K. pneumoniae strains that produce ESBLs and carbapenemase have a worldwide distribution and cause multidrug-resistant (MDR) infections in many countries. [7, 18, 19]. Carbapenems are one of the few drugs that are useful for the treatment of MDR gramnegative bacterial infections. The emergence of carbapenem resistance in Enterobacteriaceae family is a serious public health concern due to the large spectrum of resistant genes and lack therapeutic options.[20,21] Carbapenem-hydrolyzing β-lactamases belonging to molecular class A (e.g., KPC, GES, IMI, SME), class B (e.g. IMP, VIM, NDM, GIM) and class D (e.g. OXA-23 & OXA-48) and are the main source of antibiotic resistance in *Enterobacteriaceae*.[20-22] Furthermore, ESBL developing species show co-resistance to many other groups of antibiotics and limiting therapeutic options. As a result, in recent past, emergence of multidrug resistant (MDR) gram-negative bacterial infections have increased significantly and it is mainly acquired by ESBLs. [6,7, 23] Nevertheless there is still a scarcity of data on the prevalence of ESBLs and carbapenemase producing genes in patients' samples in the UAE. Although some data have been published from this region and neighbouring countries, limited number of studies are available on the genes bla<sub>TEM</sub>, bla<sub>SHV</sub>, bla<sub>CTX-M</sub>, bla<sub>NDM</sub>, bla<sub>IMP</sub> and bla<sub>OXA-48</sub> but no detailed studies on the prevalence and harboring of multiple genes in the MDR bacteria have yet been performed in the UAE. So, the current research focuses on the prevalence of class A ESBL (bla<sub>TEM</sub>, bla<sub>SHV</sub> & bla<sub>CTX</sub>-<sub>M</sub>) and class B & D carbapenemase encoding genes ( $bla_{NDM}$ ,  $bla_{IMP}$ ,  $bla_{OXA-48}$ ) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of UAE.

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Determining the prevalence of class A ESBL and class B & D carbapenemase producing genes in gram-negative bacterial pathogens is critical for effective treatment of infections caused by the MDR organisms especially in ICU and in-patients with co-morbidity cases. **Methods Ethical Approval** The present study was approved by the Institutional Review Board (IRB) of Gulf Medical University, Ajman, UAE. The approval letter from the IRB, dated October 14, 2021, indicated that the study had already received approval in the IRB meeting of September 2021 (Ref.no.IRB/COM/STD/98/Oct.2021). The study design and protocol followed the Good Clinical Practice (GCP) guidelines 2021, National Drug Abuse Treatment Clinical Trials Network. **Study Design** A laboratory based experimental study was conducted on various clinical samples such as urine, blood, pus, and sputum received from various hospitals of Northern Emirates of the UAE to the Department of Microbiology at Thumbay Laboratory, Thumbay University Hospital (TUH), Ajman, UAE. Data collection & Clinical sample processing In accordance with the IRB approval, the patients' clinical samples and other details were collected

from Thumbay Laboratory, TUH, from September 02, 2021, to June 20, 2022. But laboratory

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

analysis was performed following receipt of the IRB approval from October 14, 2021, to June 30, 2022. **Study populations** All the clinical samples were received and collected from the patients who are attending internal medicine out-patient and in patient department of TUH and other hospitals of Northern Emirates of the UAE. All the samples were received by the phlebotomy department and sent to the Microbiology department at Thumbay Laboratory, TUH to culture bacterial pathogens, staining and antibiotic sensitivity test of the isolated pathogens, and molecular detection of class A ESBL genes  $bla_{CTX-M}$ ,  $bla_{SHV}$ ,  $bla_{TEM}$  and carbapenemase producing genes  $bla_{NDM}$ ,  $bla_{IMP}$ , and  $bla_{OXA-48}$ . Upon arrival, the samples were processed for further laboratory tests. **Bacterial isolation and staining** The clinical samples were plated on MacConkey's agar to isolate the bacterial colony belongs to the Enterobacteriaceae family, Blood agar for gram positive bacterial species, Cysteine-Lactose Electrolyte Deficient (CLED) agar for urinary tract pathogens and Cetrimide Agar for Pseudomonas species isolation. All the culture plates were incubated overnight at 37°C for 18-24 hours. After the isolation of bacterial colonies from the different culture media, they were stained by Gram staining to identify them whether gram-negative or gram-positive bacteria. Bacterial identification and antibiotic sensitivity test MicroScan WalkAway automated detection system was used to identify bacterial pathogens and

to determine their ESBL and MDR nature. The bacterial inoculum was prepared from single

colonies of isolated bacteria by using the Prompt™ Inoculation System-D (Beckman Coulter, Brea, CA, USA), consisting of a wand designed to hold a specific quantity of bacteria and a 30 ml Prompt™ Inoculation Water bottle (BECKMAN COULTER, Brea, CA, USA). The inoculum was suspended thoroughly, poured in to a RENOK inoculator tray and then transferred in to MicroScan Neg Breakpoint Combo 50 panel for Gram-negative organism (BECKMAN COULTER) using RENOK inoculator (BECKMAN COULTER). The plate was incubated at 16 − 18°C in MicroScan WalkAway automated system DxM 1096 (BECKMAN COULTER). Table 1 & 1a demonstrate various tests performed on the MicroScan Neg Breakpoint Combo 50 panel. The Beckman Coulter MicroScan LabPro software WalkAway 9631049 was used to evaluate the gram-negative bacterial pathogens on their biochemical utilization and antibiotic sensitivity pattern especially ESBL and carbapenem resistant strains. The details of the MicroScan Neg Breakpoint Combo 50 panel for Gram-negative organisms are given in Supplementary table1a & 1b.

## Detection of Class A ESBL and Class B & D carbapenemase encoding

#### genes

After the identification of ESBL and MDR strains, they were sub-cultured in sterile double strength Muller Hinton broth at 37°C for 24 hours for bacterial DNA extraction with the G-spin<sup>TM</sup> for Genomic DNA extraction kit (iNtRON). The DNA extracts positive for the 16SrRNA gene in PCR assays were processed for the presence of the class A ESBL genes  $bla_{SHV}$ ,  $bla_{CTX-M}$ ,  $bla_{TEM}$  and carbapenem resistant genes  $bla_{NDM}$ ,  $bla_{IMP}$ , and  $bla_{OXA-48}$  with consensus primers in a Veriti<sup>TM</sup> 96-well Thermal cycler (Applied Bio-systems<sup>TM</sup>). The PCR assays were performed with Thermoscientific PCR Master mix kit (ThermoFisher). The PCR primers and their specifications are provided in the Table 1. Primers of all the class A ESBL and carbapenem resistant genes were

synthesized by e-oligos, Gene Link<sup>TM</sup>, NY, USA. The PCR products underwent agarose gel electrophoresis to separate the fragments of DNA and visualized the target genes which are pointed in Fig  $\underline{1}$ .

**Table 1**. PCR primers and their specifications.

Gene type	Amplicon	Primer sequence (5° – 3°)	Amplicon size (bp)	Annealing temperature °C	Reference
	bla <sub>CTX-M</sub>	F -SCSATGTGCAGYACCAGTAA R -ACCAGAAYVAGCGGBGC	585	58	
ESBL gene primers	$bla_{TEM}$	F -ATGAGTATTCAACATTTCCG R -CCAATGCTTAATCAG TGAGG	858	50	[ <u>24</u> ]
	$bla_{SHV}$	F -ATGCGTTATATTCGCCTGTG R -AGCGTTGCCAGTGCTCGATC	862	58	
	$bla_{NDM}$	F -GGTTTG GCGATCTGGTTTTC R -CGGAATGGCTCATCACGATC	621	57	[ <u>26</u> ]
Carbapenemase genes primers	$bla_{IMP}$	F -CTACCGCAGCAGAGTCTTTG R -AACCAGTTTTGCCTTACCAT	587	56	[ <u>25</u> ]
	$bla_{ m OXA48}$	F -GCGTGGTTAAGGATGAACAC R -CATCAAGTTCAACCCAACCG	438	57	[27]
Control primer	16S rRNA gene	F -AGAGTTTGATCMTGGCTCAG R -ACGGHTACCTTGTTACGACTT	1,500	55	[ <u>24</u> ]

Fig 1. Detection of bla<sub>CTX-M</sub>, bla<sub>TEM</sub>, bla<sub>SHV</sub>, bla<sub>IMP</sub> & bla<sub>NDM</sub> bands in 1% agarose gel

# Genomic sequencing and phylogenetic tree relationships of the

### *bla<sub>CTX-M</sub>*

Partial gene sequencing of the  $bla_{CTX-M}$  of the E.~coli was done by Sanger sequencing method and the sequenced product was compared with existing gene sequences in GenBank, NCBI. The cladogram of the phylogenetic tree relationship of the  $bla_{CTX-M}$  was constructed using Mega 11

software. It was constructed using the Dice coefficient with a 1% tolerance limit and 1% optimization. Cluster relatedness of collected isolates with  $\geq 70\%$  similarity was considered to indicate an identical pattern type [28, 29].

### **Statistical Analysis**

- Data were analyzed using the statistical package SPSS software version 28.0 (SPSS Inc., Chicago,
- 179 IL, USA). Descriptive data were represented as mean  $\pm$  SD. Pearson's chi-square test was
- performed in tables 3 and 4 with p-value < 0.05 considered as statistically significant.

### **RESULTS**

#### **Bacterial isolation and staining**

A total of 3670 samples were collected and processed for the routine bacterial culture. Among them, pus (n=469;12.7%), blood (n=879;24%), sputum (n=352;9.6%), urine (n=1970; 53.7%) samples were received, out of which, 1098 samples (29.9%) were positive and 2572 (70.1%) were negative for the bacterial culture. In that culture positive samples, the highest bacterial culture positivity was detected in the urine samples (49.1%; n=540), then in the pus (23%; n=253), blood (10.8%; n=119) and sputum (16.9%; n=186). In the 10986 culture positive samples, 833 (75.9%) were gram-negative and 265 (24.1%) were gram-positive bacteria and their details are given in Table 2; Fig 2.

### Bacterial identification and antibiotic susceptibility test

Among the gram-negative bacterial isolates, 249 (29.9%) were ESBL (n=209; 25.1%) and both ESBL & carbapenemase producers (n=40; 4.8%). Among the 249 bacterial isolates, 157 (63.1%) *E. coli*, 45 (18.1%) *K. pneumoniae*, 20 (8.0%) *Pseudomonas aeruginosa*, 17 (6.8%) *Proteus mirabilis*, and 10 (4.0%) *Acinetobacter baumanii* were encountered and provided in <u>Table 3</u>; Fig <u>3</u>.

**Table 2.** No. of various clinical samples for positive bacterial growth.

Clinical	bacteria	es for positive al growth (29.92%)	No. of samples for negative	Pearson's		
samples n= 3670 (%)	Gram negative bacterial growth n= 833 (75.86%)	Gram positive bacterial growth n=265 (24.14%)	bacterial growth n=2572 (70.08%)	Chi-square test		
Urine n= 1970 (53.7%)	503 (60.4%)	37 (13.96%)	1430 (55.59%)			
Blood n= 879 (23.93%)	48 (5.8%)	71 (26.8%)	760 (29.54%)	<0.0001		
Pus n= 469 (12.8%)	111 (13.3%)	142 (53.58%)	216 (8.39%)	<b>~</b> 0.0001		
<b>Sputum</b> <i>n</i> = 352 (9.6%)	171 (20.53%)	15 (5.66%)	166 (6.45%)			

Fig 2. No. of Gram -ve and gram +ve bacteria isolated from various clinical samples.

**Table 3.** Total no. of Gram-ve bacteria isolated from various clinical samples.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Gram	Γ	otal no. of ba	cteria ( <i>n=833</i> )		Pearson's
negative bacterial isolates	Urine n=503 (%)	Blood n=48 (%)	Pus n=111 (%)	Sputum n=171(%)	Chi-square test
E. coli	354 (70.37%)	8 (16.66%)	25 (22.52%)	7 (4.1%)	
K. pneumoniae	116 (23.06%)	15 (31.25%)	35 (31.53%)	34 (19.9%)	
P. aeruginosa	15 (2.98%)	9 (18.75%)	19 (17.11%)	86 (50.29%)	< 0.0001
P. mirabilis	12 (2.39%)	0	24 (21.62%)	4 (2.34%)	
A. baumannii	6 (1.19%)	16 (33.33%)	8 (7.21%)	40 (23.4%)	

**Fig 3.** Total no. of *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* in various clinical samples.

The ESBL E. coli (n=157) had shown 100% resistance to cefotaxime and ceftazidime, high medium resistance rates to Ampicillin/sulbactam, ampicillin, Aztreonam, cefazolin, cefepime, cefuroxime, (97.5%)& Amoxicillin+clavulanate (92.5%),norfloxacin (63.7%),trimethoprim/Sulfamethoxazole (58.6%), ciprofloxacin (51.6%) and levofloxacin (46.5%). Lower resistance rate to gentamycin (14.7%), tobramycin (12.7%) and least resistance rate to cefoxitin (7.6%) and absolute sensitivity to imipenem, meropenem, nitrofurantoin, piperacillin/tazobactam, tigecycline, amikacin, ertapenem, colistin. In the K. pnuemoniae isolates (n=45), all of them shown 100% resistant to the antibiotics: ampicillin, ampicillin + sulbactam, aztreonam, cefazolin, cefepime, and cefuroxime. 89% of them were resistant to amoxycillin + clavulanate and cefotaxime, whereas 66.7% - 55.6% of them were resistant to Ceftazidime, nitrofurantoin, norfloxacin, trimethoprim/sulfamethoxazole. 33.3% of the bacteria were resistant to the drug gentamycin. Nearly 22.2% of the bacteria were resistant to 9 drugs: levofloxacin, meropenem, pipracillin+tazobactum, tigecycline, tobramycin, Amikacin, cefoxitin, ertapenem

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

ciprofloxacin. 11.1% resistant to colistin, imipenem, norfloxacin. None of the K. pneumoniae had shown 100% sensitive to the above-mentioned drugs. In case of ESBL producing P. mirabilis (n=17), all were resistant to the following 10 antibiotics: tobramycin, amoxycillin+clavulanate, ampicillin, cefepime, cefazolin, cefotaxime, cefuroxime, aztreonam, trimethoprim/sulfamethoxazole and ceftazidime. 76.5% of them were shown resistance to the drugs gentamycin & amikacin. 52.9% were resistant to the drug norfloxacin, ciprofloxacin and levofloxacin. The bacteria had shown intermediate resistance to the following drugs norfloxacin, ciprofloxacin, gentamycin and ampicillin+sulbactam and they were 100% sensitive to imipenem, meropenem, nitrofurantoin, piperacillin/tazobactam, Tigecycline, cefoxitin, ertapenem & colistin. The bacteria P. aeruginosa (n=20) had shown 100% resistance to the drugs gentamycin, imipenem, levofloxacin, meropenem, tobramycin, amikacin, cefepime, ceftazidime and ciprofloxacin, 65% and 35% of them were resistant to the drugs pipracillin+tazobactum and Aztreonam respectively and none of them were 100% sensitive to any antibiotics which are used in the test except colistin. Similarly, the bacteria A. baumannii (n=10) had shown 100% resistance to 11 different drugs, those were amikacin, cefepime, ciprofloxacin, gentamycin, imipenem, levofloxacin, meropenem ceftazidime. 80% of the strains were resistant to ampicillin + sulbactam. trimethoprim/sulfamethoxazole and tobramycin, and 30% of them were resistant to colistin. The details are given in Table 4; Fig 4.

Table 4. Antibiotic sensitivity pattern of *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* isolated from various
 clinical samples.

Antibiotics	1	E. coli n= 157 (	(%)	-	pneumon n=45 (%)			P. mirabili n=17 (%)			aerugin 1=20 (%	<b>I</b>		bauma n=10 (%	
	S	I	R	S	I	R	S	I	R	S	I	R	S	I	R
Gentamicin	134 (85.4%)	0	23 (14.6%)	30 (66.7%)	0	15 (33.3%)	0	4 (23.5%)	13 (76.5%)	0	0	20 (100%)	0	0	10 (100%)
Imipenem	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 (100%)	0	0	0	0	20 (100%)	0	0	10 (100%)
Levofloxacin	84 (53.5%)	0	73 (46.5%)	35 (77.8%)	0	10 (22.2%)	9 (52.9%)	0	8 (47.1%)	0	0	20 (100%)	0	0	10 (100%)
Meropenem	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	0	20 (100%)	0	0	10 (100%)
Nitrofurantoin	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 (100%)	0	0	0	0	0	0	0	10 (100%)
Norfloxacin	57 (36.3%)	0	100 (63.7%)	40 (88.9%)	0	5 (11.1%)	0	8 (47.1%)	9 (52.9%)	0	0	0	0	0	10 (100%)
Piperacillin /Tazobactam	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	7 (35%)	13 (65%)	0	0	0
Tigecycline	157 (100%)	0	0	30 (66.7%)	5 (11.1%)	10 (22.2%)	17 (100%)	0	0	0	0	0	0	0	0
Tobramycin	130 (82.8%)	7 (4.5%)	20 (12.7%)	30 (66.7%)	5 (11.1%)	10 (22.2%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Trimethoprim/ Sulfamethoxazole	65 (41.4%)	0	92 (58.6%)	20 (44.4%)	0	25 (55.6%)	0	0	17 (100%)	0	0	0	0	2 (20%)	8 (80%)
Amikacin	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	4 (23.5%)	0	13 (76.5%)	0	0	20 (100%)	0	0	10 (100%)
Amoxicillin/ Clavulanate	12 (7.6%)	0	145 (92.4%)	5 (11.1%)	0	40 (88.9%)	0	0	17 (100%)	0	0	0	0	0	0
Ampicillin/ sulbactam	4 (2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	4 (23.5%)	13 (76.5%)	0	0	0	0	3 (30%)	7 (70%)

Ampicillin	0	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Aztreonam	4 (2.5%)	0	153 (97.5%)	14 (31.1%)	0	31 (68.8%)	0	0	17 (100%)	0	13 (65%)	7 (35%)	0	0	0
Cefazolin	(2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Cefepime	4 (2.5%)	0	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Cefotaxime	0	0	157 (100%)	0	5 (11.1%)	40 (88.9%)	0	0	17 (100%)	0	0	0	0	0	0
Cefoxitin	138 (87.9%)	7 (4.5%)	12 (7.6%)	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	0	0	0	0	0
Ceftazidime	0	0	157 (100%)	15 (33.3%)	0	30 (66.7%)	0	0	17 (100%)	0	0	20 (100%)	0	0	10 (100%)
Cefuroxime	0	4 (2.5%)	153 (97.5%)	0	0	45 (100%)	0	0	17 (100%)	0	0	0	0	0	0
Ciprofloxacin	76 (48.4%)	0	81 <i>(51.6%)</i>	30 (66.7%)	5 (11.1%)	10 (22.2%)	0	8 (47.1%)	9 (52.9%)	0	0	20 (100%)	0	0	10 (100%)
Ertapenem	157 (100%)	0	0	35 (77.8%)	0	10 (22.2%)	17 (100%)	0	0	0	0	0	0	0	0
colistin	157 (100%)	0	0	40 (88.9%)	0	5 (11.1%)	17 (100%)	0	0	20 (100%)	0	0	7 (70%)	0	3 (30%)

**Fig 4.** Heatmap of antibiotic sensitivity pattern of E. coli, K. pneumoniae, P. mirabilis, P.

aeruginosa, and A. baumannii.

### Detection of Class A ESBL and Class B & D carbapenemase encoding

#### genes

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

All the ESBL and carbapenem resistant bacteria (n=249) had positive to all the 3 ESBL genes and carbapenem resistant genes bla<sub>NDM</sub> & bla<sub>IMP</sub> either harbored single or multiple. Among the 249 isolates, the E. coli (n=157; 63.1%) harbored all the ESBL genes and among them, the bla<sub>CTX-M</sub> (n=72; 45.9%) was predominantly identified, then  $bla_{TEM}(n=59; 37.6\%)$  and  $bla_{SHV}(n=31; 19.7\%)$ respectively. Of 157 E. coli, 20.33% (n=32) of them co-harbored more than one gene like bla<sub>CTX</sub>.  $_{M+TEM}$  or  $bla_{CTX-M+SHV}$  or altogether. In that gene combination, the  $bla_{CTX-M+TEM}$  (n=15; 9.55%) & bla<sub>CTX-M+SHV</sub> (n=15; 9.55%) were detected in 15 E. coli strains and all the 3 genes were identified together in 3.8% of the E. coli. Similarly, the bla<sub>CTX-M</sub> (40%; n=18) was the predominant gene even in the MDR K. pneumoniae (n=45), followed by the  $bla_{TEM}$  (31.1%; n=14),  $bla_{SHV}$  (31.1%; n=14),  $bla_{IMP}$  (13.33%; n=6) and  $bla_{NDM}$  (2.22%; n=1) respectively. The gene combinations such as either the  $bla_{CTX-M}+_{TEM}$  (n=14; 31.1%) or  $bla_{CTX-M}+_{SHV}$  (n=10; 22.2%) or  $bla_{TEM}+_{SHV}$  (6.6%; n=3) or  $bla_{TEM}+_{NDM}$  (2.22%; n=1) were detected in 62.22% of the K. pneumoniae. Likewise in the P. aeruginosa, the genes  $bla_{CTX-M}$  and  $bla_{TEM}$  were detected in almost all the isolates. Of which, the  $bla_{IMP}$  was detected in 7 (35%) strains and the  $bla_{SHV}$  was detected in 13 (65%) strains. The gene combination such as  $bla_{CTX-M+SHV}$  (5%; n=1) and  $bla_{CTX-M+TEM+SHV+IMP}$  (5%; n=1) were detected in 10% of the organism. In the same manner, the gene  $bla_{CTX-M}$  was detected in all the 17 ESBL positive P. mirabilis (100%), the  $bla_{TEM}$  was detected in 8 strains (47.1%) and among the 17 P. mirabilis strains, 17.6% (n=3) of them had positive to both the genes ( $bla_{CTX-M+TEM}$ ). The above

resistant genes holding bacterial strains were predominantly isolated from the urine and pus samples and the details are presented in Table 5; Fig 5.

Table 5. Number of class A ESBL and class B carbapenemase encoding genes in number of *E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis* and *A. baumannii* isolated from various clinical samples.

	FSDI	& Carbapenem		Single	gene de	tection				Multipl	e gene de	etection			
Clinical Samples (n=833)		resistant	bla <sub>CTX-M</sub> n=111 (%)	bla <sub>TEM</sub> n=85 (%)	bla <sub>SHV</sub> n=45 (%)	bla <sub>NDM</sub> n=3 (%)	bla <sub>IMP</sub> n=6 (%)	bla <sub>CTX-M</sub> +TEM n=33 (%)	bla <sub>CTX-M</sub> +SHV n=26 (%)	bla <sub>TEM</sub> +SHV n=3 (%)	bla <sub>CTX-M</sub> +TEM +SHV n= 6 (%)	bla <sub>TEM</sub> +NDM n=2 (%)	bla <sub>TEM</sub> +IMP n=1 (%)	bla <sub>CTX-M</sub> +TEM+SHV +IMP n=2 (%)	
		E. coli n=120 (76.9%)	56 (46.7%)	44 (36.7%)	20 (16.7%)	0	0	11 (9.2%)	11 (9.2%)	0	6 (5%)	0	0	0	
<b>T</b> I •		K. pnuemoniae n=28 (17.9%)	8 (28.6%)	10 (35.7%)	7 (35.7%)	0	3 (21.4%)	8 (28.6%)	7 (25%)	3 (10.7%)	0	0	0	0	
Urine (n=503)	n=156 (31%)	<i>P. aeruginosa</i> n=5(3.2%)	2 (40%)	2 (40%)	1 (20%)	0	0	0	0	0	0	0	0	0	0.0147
		P. mirabilis n=3 (1.9%)	2 (66.7%)	1 (33.3%)	0	0	0	1 (33.3%)	0	0	0	0	0	0	
		A. baumannii (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
		E. coli n=7 (50%)	5 (71.4%)	1 (14.3%)	1 (14.3%)	0	0	1 (14.3%)	0	0	0	0	0	0	
DI I		<i>K. pnuemoniae</i> n=2 (14.3%)	1 (50%)	1 (50%)	0	0	0	0	0	0	0	0	0	0	
Blood (n=48)	n=14 (29.2%)	P. aeruginosa n=2 (14.3%)	1 (50%)	0	1 (50%)	0	0	0	0	0	0	0	0	0	0.7933
		P. mirabilis (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
		A. baumannii n=3 (1.9%)	2 (66.7%)	1 (33.3%)	0	0	0	0	0	0	0	0	0	0	
D		E. coli n=25 (51%)	8 (32%)	10 (40%)	7 (28%)	0	0	3 (12%)	3 (12%)	0	0	0	0	0	
Pus (n=111)	n=49 (44.1%)	<i>K. pnuemoniae</i> n=7 (14.3%)	5	1 (14.3%)	1	0	0	3	2 (28.6%)	0	0	0	0	0	0.0054
		P. aeruginosa n=3 (6.1%)	1 (33.3%)	1	0	0	1 (33.3%)	0	0	0	0	0	0	0	

	P. mirabilis n=14 (28.6%)	8 (57.1%)	4 (42.9%)	0	0	0	2 (14.3%)	0	0	0	0	0	0	
	A. baumannii (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
	E. coli n=5 (16.66%)	3 (60%)	1 (20%)	1 (20%)	0	0	0	1 (20%)	0	0	0	0	0	
	<i>K. pnuemoniae</i> n=8 (26.66%)	4 (50%)	2 (25%)	1 (12.5%)	1 (12.5%)	0	3 (37.5%)	1 (12.5%)	0	0	1 (12.5%)	0	0	
Sputum (n=171)	P. aeruginosa n=10 (33.33%)	3 (42.9%)	5 (28.6%)	1 (14.3%)	0	1 (14.3%)	1 (14.3%)	1 (14.3%)	0	0	0	0	1 (14.3%)	0.7354
	P. mirabilis (n=0)	0	0	0	0	0	0	0	0	0	0	0	0	
	A. baumannii n=7 (23.33%)	2 (28.6%)	1 (14.3%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	0	0	0	0	1 (14.3%)	1 (14.3%)	1 (14.3%)	
271														

Fig 5. Heatmap of frequency of class A ESBL and class B carbapenemase encoding genes in E. coli, K. pneumoniae, P. aeruginosa, P.

mirabilis and A. baumannii isolated from various clinical samples.

Table 6. Frequency of detection of class A ESBL and class B carbapenemase encoding genes in E. coli, K. pneumoniae, P. aeruginosa,

## P. mirabilis and A. baumannii.

281

282

ESBL &		Single ş	gene detec	ction			Multiple gene detection							
Carbapenem resistant G-ve bacteria (n=249)	bla <sub>CTX-M</sub> n=111 (%)	bla <sub>TEM</sub> n=86 (%)	bla <sub>SHV</sub> n=43 (%)	bla <sub>NDM</sub> n=3 (%)	bla <sub>IMP</sub> n=6 (%)	bla <sub>CTX-M</sub> +TEM n=33 (%)	bla <sub>CTX-M</sub> +SHV n=26 (%)	bla <sub>TEM</sub> +SHV n=3 (%)	bla <sub>CTX-M</sub> +TEM+SHV n=6 (%)	bla <sub>TEM</sub> +NDM n=2 (%)	bla <sub>TEM</sub> +IMP n=1 (%)	bla <sub>CTX-M</sub> +TEM+SHV +IMP n=2 (%)	Pearson's Chi- square test	
E. coli (n=157)	72 (45.85%)	56 (35.65%)	29 (18.5%)	0	0	15 (9.55%)	15 (9.55%)	0	6 (3.82%)	0	0	0		
<i>K. pnuemoniae</i> (n=45)	18 (40%)	14 (31.1%)	9 (20%)	1 (2.2%)	3 (6.7%)	14 (31.1%)	10 (22.2%)	(6.66%)	0	1 (2.22%)	0	0		
P. aeruginosa (n=20)	7 (35%)	8 (40%)	3 (15%)	0	2 (10%)	(5.0%)	(5.0%)	0	0	0	0	1 (5.0%)	<0.0001	
P. mirabilis (n=17)	10 (58.8%)	6 (35.3%)	1 (5.9%)	0	0	3 (17.65%)	0	0	0	0	0	0		
A. baumannii (n=10)	4 (40%)	2 (20%)	1 (10%)	2 (20%)	1 (10%)	0	0	0	0	1 (10%)	1 (10%)	1 (10%)		

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

All the A. baumannii (n=10; 100%) had positive to the gene  $bla_{CTX-M}$  and  $bla_{TEM}$ , 20% (n=2) of the strains individually had the gene  $bla_{NDM}$  and  $bla_{SHV}$ , and the  $bla_{IMP}$  was detected in 10% of the A. baumannii isolates of the sputum samples. The gene combination  $bla_{TEM+NDM}$   $bla_{TEM+IMP}$  and bla<sub>CTX-M+TEM+SHV+IMP</sub> were detected separately in 10% (n=1) of the strains. In none of the ESBL and carbapenem producers, the class D carbapenemase gene bla<sub>OXA-48</sub> was not detected, and the above-mentioned details are given in <u>Table 6</u>; Fig <u>6</u>. Fig 6. Frequency of detection of class A ESBL and class B & D carbapenemase encoding genes in E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis and A. baumannii. Genomic sequencing and phylogenetic tree relationships of the bla<sub>CTX-M</sub> The gene  $bla_{CTX-M}$  was isolated and polymerized from the bacteria  $E.\ coli$  isolated from the urine sample. Partial gene sequencing of the *bla<sub>CTX-M</sub>* was deposited in the GenBank, NCBI and obtained accession number 2780010. The cladogram of the phylogenetic tree was constructed using 99.74% similarity identification with various E. coli & K. pneumoniae bla<sub>CTX-M</sub> genes which are already deposited in the GenBank, and the cladogram of the tree is given in Fig 7. Fig 7. Cladogram of the phylogenetic tree of the class A ESBL gene  $bla_{CTX-M}$  isolated from the ESBL E. coli.

#### **DISCUSSION**

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

Over the recent decades, the spread of ESBL producing *Enterobacteriaceae* has risen as a global concern because of substantial increases in mortality and morbidity and making it difficult to treat infections.[30] Reduced treatment options, complex infections, and costly treatments are some of the major concerns for people infected with ESBL-producing organisms [31]. A major driver of ESBL producing Gram-negative bacteria is the horizontal transfer of mobile genetic elements carrying genes for ESBL and/or carbapenemase enzyme production [32]. The present study collected 3670 various clinical samples, of which the urine samples were predominantly (51.2%) received and had shown the highest bacterial growth rate (49.1%). The bacterial growth rate was significant among the collected samples and the overall positivity rate of the bacterial growth was 29.9%. Similarly, a study was carried out in Abu Dhabi [33] reported that the urine sample was the most common sample type (24.2%), followed by sputum, wound and blood respectively and Mahamat et al. stated that in their study the predominant clinical samples were urine (72.5%) than other clinical samples and the highest bacterial growth (70.3%) rate was observed from the urine samples [33, 34] In this study, 64.3% of the bacterial isolates were gram-negative bacteria and remaining 35.7% were gram positive bacteria (21.5%) and other gram variable bacteria & Candida species (14.2%). Among the gram-negative bacteria, the E. coli (42.3%) was the most predominant isolates followed by K. pneumoniae (19.4%), P. aeruginosa (13.5%), A. baumanii (7.3%) and P. mirabilis (3.3%). Likewise, National AMR Surveillance system of the UAE reported (in 2020) that the E. coli was the most commonly (80%) isolated gram-negative bacteria, then K. pneumoniae (55%-60%), P. aeruginosa (20%), A. baumannii (<10%) and P. mirabilis (<5%) [35]. In our study, the ESBL E. coli had shown 100% resistance to cefotaxime and ceftazidime, similarly, the study was

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

conducted by Al-Agamy et al. and Kabrah found 100% resistance to the same drugs by the ESBL E. coli [36, 37]. High - medium resistance rates (97.5% - 46.5%) were detected to 11 different antibiotics. The authors Kasim OA (2019), Shaaban et al. (2021) & Mohammed et al (2022) from Bahrain, Alfaresi et al. (2018) & Karlowsky et al. (2022) from UAE were found that high-medium resistance to the same drugs in their studies [38-42]. Lower resistance rate to gentamycin (14.7%), tobramycin (12.7%), least resistance to cefoxitin (7.6%) and 100% sensitivity to 8 different antibiotics which are mentioned in Table 4. Likely the Kasim OA, Perez-Lopez et al from Qatar and Al-Tawfig et al. from Saudi Arabia were noted the same results in their studies [38, 43, 44]. The ESBL K. pneumoniae were 100% resistant to ampicillin, aztreonam, cefazolin, cefepime and cefuroxime. Multiples studies from different GCC region including UAE reported the pattern of sensitivity to the same drugs [40, 42, 45-47]. Higher resistance rate (89%) was identified on cefotaxime and amoxicillin+clavulanate and this was like the study from Bahrain [38], but lower - medium resistance rate was observed to the above drugs in various studies conducted in Kuwait, UAE, Qatar and Saudi Arabia [37, 43, 47, 48]. The bacteria had shown lower resistance rate (22.2%) to tigecycline, meropenem and other antibiotics and the studies from KSA [49, 50] reported that the resistance rate has increased from 8% to 23.4% almost like the current study. The resistant rate was 11.1% to colistin & imipenem and the rate has increased from 0% to 11.1% during the past 5 years in UAE [41]. The P. mirabilis was 100% resistance and 100% sensitive to 10 and 8 different antibiotics respectively and are mentioned in the Table 4 and high – medium resistance rate (76.5% - 53%) had identified to gentamycin, amikacin, ampicillin/sulbactam, ciprofloxacin and norfloxacin. Rather JI et al. stated the same finding on the P. mirabilis [51]. But in contrast, the current resistant rate was slightly higher than the study reported from China [52].

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

The bacteria P. aeruginosa were 100% resistant to 9 different drugs and 100% susceptible to colistin and medium – low resistance rate was noted to piperacillin/tazobactam (65%) and aztreonam (35%). In contrast to our study, the studies from Sudan [53] and Egypt [54] observed that the bacteria had low resistance rate and high susceptible to the above-mentioned drugs. In the case of A. baumannii, the bacteria were 100% resistant to 11 drugs which are given in the table 4, higher resistance rate (70% - 80%) was observed on the ampicillin/sulbactam & trimethoprim/sulfamethoxazole and 30% resistance to colistin. This was very high resistance compared with studies from Oman [55] and Iran [56]. Resistance to the colistin is rapidly emerging among the MDR A. baumannii and K. pneumoniae, which has become a global burden. At present, more than 300 different ESBL variants have been identified, the CTX-M, SHV and TEM are the most reported in several areas of the world [57]. The UAE is considered among the GCC countries with the moderate rate of ESBL production among the *Enterobacteriaceae* [41, 58]. In the present study, all the 3 ESBL genes were detected in all the bacterial isolates. Among them, the bla<sub>CTX-M</sub> was predominantly harbored, mostly in the E. coli (45.9%), P. mirabilis (58.8%), K. pneumoniae (42.2%), A. baumannii (40%) and P. aeruginosa (35%). Previous studies from different countries in the GCC region, stated that the  $bla_{CTX-M}$  was the dominant gene among ESBL Enterobacterales (100%), E. coli (55.5%-100%) and K. pneumoniae (32.1% - 100%) across different sample types and clinical settings [41,45,48,59,60]. After that *bla*<sub>TEM</sub> and *bla*<sub>SHV</sub> were the next commonly detected genes and mainly in the E. coli (35.6% & 18.5%) and K. pneumoniae (16.4% & 26.7%). Similarly in the UAE, Alfaresi et al. stated that the bla<sub>CTX-M</sub> was the dominant gene followed by  $bla_{TEM}$  and  $bla_{SHV}$  in their study and Eltai et al. found the same dominant gene similarity in their study [41, 59]. In contrast to our results, a study from Iraq stated that the  $bla_{TEM}$ 

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

was the most predominant gene in the *Enterobacterales* then followed by  $bla_{CTX-M}$  &  $bla_{SHV}$ . [61] Likewise, Bajpai et al. also reported the same as the most prevalent gene was  $bla_{TEM}$  and the  $bla_{SHV}$ [62] and in Zaki study the  $bla_{SHV}$  (61.22%) was the most detected gene [63]. The carbapenemase encoding gene bla<sub>IMP</sub> was detected in 13.3% of K. pneumoniae isolated from the urine samples and in 10% of A. baumannii from sputum & 10% of P. aeruginosa from both the samples. Like this, 20% of the A. baumannii and 2.22% of K. pneumoniae harbored the bla<sub>NDM</sub> and they were isolated from the sputum samples. Almost 94% of them were positive to the  $bla_{IMP}$ in Bharain [64] but 6% of the A. baumannii were positive to the  $bla_{NDM}$ . 8.7% of the K. pneumoniae were positive to the bla<sub>IMP</sub> in 2019, Saudi Arabia [46], Perez-Lopez et al. [43] reported that 3% of E. coli & 2.4% of the E. coli were positive to the bla<sub>NDM</sub> and bla<sub>OXA-48</sub> respectively, and 12.9% & 3.2% of the K. pneumoniae were harbored the same genes. Moreover, the gene  $bla_{OXA-48}$  was commonly identified among the Enterobacteriaceae in other countries including like Saudi Arabia and Egypt [65-67]. However, in our study, none of the ESBL and the carbapenem resistant bacteria harbored the gene bla<sub>OXA-48</sub>. But in contrast to our study, Kamel NA et al. from Egypt reported that 6% E. coli, 9.4% Klebsiella spp, & 3.1% of each P. aeruginosa and A. baumannii were positive to the  $bla_{NDM}$  and none of the gram-negative bacteria were carried the  $bla_{IMP}$  in their study, but they were positive to the  $bla_{OXA-48}$ . [68] The highest co-existence patterns were  $bla_{CTX-M+TEM}$  and  $bla_{CTX-M+SHV}$  represented by E. coli (9.6%) of each), K. pneumoniae (31.1% & 22.2%) & P. aeruginosa (15% of each). In 17.65% of the P. mirabilis the only co-existence gene was  $bla_{CTX-M+TEM}$ . The lowest co-existence patterns were bla<sub>TEM+SHV</sub> & bla<sub>CTX-M+TEM+SHV</sub> represented by K. pneumoniae (6.67%) and E. coli (3.82%) respectively. Similarly, the highest co-existence of the gene  $bla_{CTX-M+TEM}(21\%)$  was found in the ESBL E. coli & K. pneumoniae from Qatar [59], Saudi Arabia [45, 69] and followed by the least

co-existence of the genes  $bla_{TEM+SHV}$ ,  $bla_{CTX-M+SHV}$  &  $bla_{CTX-M+TEM+SHV}$  were detected in their same studies, but in contrast, the Moglad et al, Badger-Emeka et al and Sid Ahmed et al found that the highest co-harbored genes were  $bla_{CTX-M+TEM+SHV}$  (50% & 24.7%),  $bla_{CTX-M+SHV}$  (50% & 10.1%) found in the E. coli, K. pneumoniae and other Enterobacterales in their studies. [70,71] Likewise, the lowest co-expression of the genes  $bla_{TEM+NDM}$ ,  $bla_{TEM+IMP}$  and  $bla_{CTX-M+TEM+SHV+IMP}$  were also detected in 2.22% K. pneumoniae, 5% P. aeruginosa and 10% of each A. baumannii to each gene combination. In such a way, Elbadawi HS et al. found in their study that the lowest co-expression of the ESBL and carbapenemase producing genes were noticed in the K. pneumoniae, A. baumannii, E. coli and P. aeruginosa. [72]

#### **CONCLUSION**

The current findings confirm UAE to have a slightly high prevalence of class A ESBL and class B carbapenemase encoding genes. According to the study the gene  $bla_{CTX-M}$ ,  $bla_{TEM}$  and  $bla_{SHV}$  were the most detected in the  $E.\ coli$  and  $K.\ pneumoniae$  especially isolated from the urine samples. The highest percentage of the bacteria  $K.\ pneumoniae$  harbored all the class A ESBL & class B carbapenemase encoding genes and, the multiple two gene combinations like  $bla_{CTX-M+TEM}$ ,  $bla_{CTX-M+TEM}$ ,  $bla_{TEM+SHV}$  &  $bla_{TEM+NDM}$  as well and then  $A.\ baumannii$  also harbored all the class A ESBL and class B carbapenemase encoding genes and also they co-harbored the genes  $bla_{TEM+NDM}$ ,  $bla_{TEM+NDM}$ ,  $bla_{CTX-M+TEM+SHV+IMP}$ . The current results emphasize the significance of rational antibiotic therapy and ongoing stringent surveillance and infection control strategies to successfully curb the spread of these ESBL and carbapenemase encoding genes in the gram – ve bacteria and become multidrug resistant pathogens.

## **Limitations of the study**

- 418 As of all other studies this study also reported few limitations as follow.
- 419 a. The study samples received from various hospitals, clinics and Thumbay hospitals located in
- and around the northern emirates of UAE (Fujairah, Umm-Al-Quwain, Ajman, and Sharjah)
- and not received the samples from other emirates (Ras-Al-Khaimah, Dubai & Abu Dhabi).
- 422 b. The class D carbapenemase encoding gene  $bla_{OXA-48}$  was detected in none of the ESBL and
- carbapenem resistant gram ve bacterial pathogens even in A. baumannii. In this study, partial
- sanger sequencing of the predominant *gene blaCTX-M* was done but the other next
- predominant class A genes  $bla_{TEM}$  &  $bla_{SHV}$  could not be able to do the sanger sequencing.

# **Supporting Information**

- 427 Supplementary table 1a Test wells on the MicroScan Gram-negative panels (Neg Breakpoint
- 428 Combo 50).

426

417

- 429 Supplementary table 1b Antibiotic sensitivity test wells on the MicroScan Gram-negative
- 430 panels (Neg Breakpoint Combo 50).
- 431 S1 File. For each variable of interest, give sources of data and details of methods of assessment
- 432 (measurement). Describe comparability of assessment methods if there is more than one group.
- 433 S2 File. (a) Report numbers of individuals at each stage of study—e.g., numbers potentially
- eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up,
- and analyzed.
- 436 **S3 file.** Flow diagram of the study.
- 437 **S4 File.** Cross-sectional study—Report numbers of outcome events or summary measures.

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

S5 File. Cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. **Acknowledgments** We would like to acknowledge the efforts of Physicians, Microbiologists and other relevant staffs of Thumbay Laboratory and Thumbay University Hospital, Ajman, U.A.E for collecting the gram -negative bacterial pathogens and data and conducting this study. Also want to express our gratitude to the College of Medicine, GMU for the constant support to conduct this research. **Author contributions Conceptualization:** Nazeerullah Rahamathullah **Data curation:** Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq, Mariam Aylu Mobiddo. **Formal analysis:** Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq, Mariam Aylu Mobiddo. **Investigation:** Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq, Mariam Aylu Mobiddo. **Methodology:** Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq, Mariam Aylu Mobiddo, Alaa Kamian. **Project administration:** Nazeerullah Rahamathullah, Nasir Parwaiz. **Software:** Nazeerullah Rahamathullah, Premalatha Ragupathi, Vaneezeh Kasmian.

- 457 **Supervision:** Nazeerullah Rahamathullah, Mohammad Shahid Akhtar, Nasir Parwaiz.
- 458 **Validation:** Nazeerullah Rahamathullah, Sovan Bagchi.
- 459 Writing original draft: Premalatha Ragupathi, Vaneezeh Khamisani, Aisha Fadila Sadiq,
- 460 Mariam Aylu Mobiddo, Nazeerullah Rahamathullah, Sovan Bagchi.
- Writing review & editing: Nazeerullah Rahamathullah, Sovan Bagchi.

## References

462

463

- 1. McCarthy M. Woman dies after infection with bacteria resistant to all antibiotics available in
- 465 US. *BMJ*. 2017; 356:254. <a href="https://doi.org/10.1136/bmj.j254">https://doi.org/10.1136/bmj.j254</a> PMID: 28096073.
- 466 2. de Kraker M.E.A.; Stewardson A.J.; Harbarth S. Will 10 Million People Die a Year due to
- 467 Antimicrobial Resistance by 2050? *PloS Med.* 2016; 13(11):e1002184.
- https://doi.org/10.1371/journal.pmed.1002184 PMID: 27898664.
- 3. Breijyeh Z.; Jubeh B.; Karaman R. Resistance of Gram-Negative Bacteria to Current
- Antibacterial Agents and Approaches to Resolve It. *Molecules*. 2020; 25(6),1340.
- 471 https://doi.org/10.3390/molecules25061340 PMID: 32187986.
- 472 4. Tooke C.L.; Hinchliffe P.; Bragginton E.C.; Colenso C.K.; Hirvonen V.H.A.; Takebayashi
- Y.; et al. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019;
- 474 431(18): 3472-3500. https://doi.org/10.1016/j.jmb.2019.04.002 PMID: 30959050.
- 5. Exner M.; Bhattacharya S.; Christiansen B.; Gebel J.; Gbermes P.G.; Hartemann P.; et al.
- 476 Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?
- 477 *GMS Hygiene and Infection Control.* 2017; 12:1-24. https://doi.org/10.3205/dgkh000290
- 478 PMID: 28451516.

- 6. Rawat D.; Nair D. Extended-spectrum β-lactamases in Gram Negative Bacteria. *J Glob Infect*
- 480 *Dis.* 2010; 2(3):263. <a href="https://doi.og/10.4103/0974-777x.68531">https://doi.og/10.4103/0974-777x.68531</a> PMID: 20927289.
- 481 7. Hawkey P.M.; Jones A.M. The changing epidemiology of resistance. *J Antimicrob*
- 482 *Chemother.* 2009; 64, Suppl. 1, i3–i10. https://doi.org/10.1093/jac/dkp256 PMID: 19675017.
- 483 8. Ambler R.P. The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci.* 1980;
- 484 289(1036):321-31. https://doi.og/10.1098/rstb.1980.0049 PMID: 6109327.
- 485 9. Ambler R.P.; Coulson A.F.; Frère J.M.; Ghuysen J.M.; Joris B.; Forsman M.; et al. A standard
- numbering scheme for the class A beta-lactamases. Biochem J. 1991; 276 (1)(1):269-70.
- 487 <u>https://doi.org/10.1042/bj2760269</u> PMID: <u>2039479</u>.
- 488 10. Bush K.; Jacoby G.A. Updated Functional Classification of β-Lactamases. *Antimicrob Agents*
- 489 *Chemother.* 2010; 54 (3):969-976. https://doi.org/10.1128/aac.01009-09 PMID: 19995920.
- 490 11. Kong K.F.; Schneper L.; Mathee K. Beta-lactam Antibiotics: From Antibiosis to Resistance
- 491 and Bacteriology. *APMIS*. 2010; 118(1):1-36. https://doi.org/10.1111/j.1600-
- 492 0463.2009.02563.x PMID: 20041868.
- 493 12. Kapoor G.; Saigal S.; Elongavan A. Action and resistance mechanisms of antibiotics: A guide
- for clinicians. J Anaesthesiol Clin Pharmacol. 2017; 33(3):300-305.
- 495 https://doi.org/10.4103/joacp.JOACP 349 15 PMID: 29109626.
- 496 13. Zhao W.H.; Hu Z.Q. Epidemiology and genetics of CTX-M extended-spectrum β-lactamases
- in Gram-negative bacteria. Crit Rev Microbiol. 2013; 39(1):79-101.
- 498 https://doi.org/10.3109/1040841X.2012.691460 PMID: 22697133.
- 499 14. Bernard H.; Tancrede C.; Livrelli V.; Morand A.; Barthelemy M.; Labia R. A novel plasmid-
- mediated extended-spectrum b-lactamase not derived from TEM- or SHV-type enzymes. J.

- 501 Antimicrob. Chemother. 1992; 29, 590–592. https://doi.org/10.1093/jac/29.5.590 PMID:
- 502 1624397.
- 503 15. Ahmed A.R.; Neveen A.A.; Magdy A.A.; Ramy K.A. Novel blaCTX-M variants and
- genotype-phenotype correlations among clinical isolates of extended spectrum beta-
- lactamase-producing Escherichia coli. Sci Rep. 2019; 9(1):4224.
- 506 https://doi.org/10.1038/s41598-019-39730-0 PMID: 30862858.
- 507 16. Dionysios A.A.; Rida A.; Karam A.R.; Thomas B.; Christopher B.; Neal C.; et al. PATRIC as
- a unique resource for studying antimicrobial resistance. *Briefings in Bioinformatics*. 2019;
- 509 20(4):1094–1102. https://doi.org/10.1093/bib/bbx083 PMID: 28968762.
- 510 17. Chong Y.; Shimoda S.; Shimono N. Current epidemiology, genetic evolution and clinical
- 511 impact of extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella*
- 512 pneumoniae. Infect Genet Evol. 2018; 61:185-188.
- 513 <u>https://doi.org/10.1016/j.meegid.2018.04.005</u> PMID: <u>29626676</u>.
- 18. Livermore D.M. Has the era of untreatable infections arrived? *J Antimicrob Chemother*. 2009;
- 515 64(1): 29-36. https://doi.org/10.1093/jac/dkp255 PMID: 19675016.
- 516 19. Mahony M.; McMullan B.; Brown J.; Kennedy S.E. Multidrug-resistant organisms in urinary
- 517 tract infections in children. *Pediatr Nephrol*. 2020; 35(9):1563-1573.
- 518 https://doi.org/10.1007/s00467-019-04316-5 PMID: 31418063.
- 519 20. Cantón R.; Akóva M.; Carmeli Y.; Giske C.G.; Glupczynski Y.; Gniadkowski M.; et al. Rapid
- evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol
- 521 Infect. 2012; 18(5). https://doi.org/10.1111/j.1469-0691.2012.03821.x PMID: 22507109.

- 522 21. Poirel L.; Pitout J.D.; Nordmann P. Carbapenemases: molecular diversity and clinical
- 523 consequences. Future Microbiol. 2007; 2(5). https://doi.org/10.2217/17460913.2.5.501
- 524 PMID: 17927473.
- 525 22. Steinmann J.; Kaase M.; Gatermann S.; Popp W.; Steinmann E.; Damman M.; et al. Outbreak
- due to a *Klebsiella pneumoniae* strain harboring KPC-2 and VIM-1 in a German university
- 527 hospital, July 2010 to January 2011. Euro Surveill. 2011; 16(33):19944.
- 528 https://pubmed.ncbi.nlm.nih.gov/21871227/ PMID: 21871227.
- 529 23. Tufa T.B; Mackenzie C.R; Orth H.M; Wienemann O; Nordmann T; Abdissa S. et al.
- Prevalence and characterization of antimicrobial resistance among gram-negative bacteria
- isolated from febrile hospitalized patients in central Ethiopia. Antimicrob Resist Infect
- 532 *Control.* 2022; 11(1):8:1-12. https://doi.org/10.1186/s13756-022-01053-7 PMID: 35033191.
- 533 24. Tofteland S.; Haldorsen B.; Dahl K.H; Simonsen G.S.; Steinbakk M; Walsh T.R; et al.
- Norwegian ESBL Study Group: Effects of phenotype and genotype on methods for detection
- of extended-spectrum-beta-lactamase-producing clinical isolates of *Escherichia coli* and
- 536 Klebsiella pneumoniae in Norway. J Clin Microbiol. 2007; 45:199–205.
- 537 <u>https://doi.org/10.1128/JCM.01319-06</u> PMID: <u>17079502</u>.
- 538 25. Murray P.R.; Baron E.J.; Jorgensen J.H; Landry M.L; Pfaller M.A. Detection and
- characterization of antimicrobial resistance genes in pathogenic bacteria. In Manual of
- Clinical Microbiology. *American Society for Microbiology* 2007; 9:1250-1256.
- 541 26. Nordmann P; Naas T; Poirel L. Global spread of carbapenemase-producing
- Enterobacteriaceae. Emerging infectious diseases. 2011; 17(10):1791.
- 543 https://doi.org/10.3201/eid1710.110655 PMID:22000347.

- 544 27. Poirel L; Walsh T.R; Cuvillier V; Nordmann P. Multiplex PCR for detection of acquired
- carbapenemase genes. Diagnostic microbiology and infectious disease. 2011; 70(1):119-23.
- 546 https://doi.org/10.1016/j.diagmicrobio.2010.12.002 PMID: 21398074.
- 28. Atschul S.F; Madden T.L; Schaffer A.A; Zhang J; Zhang Z; Miller W. et al. Gapped BLAST
- and PSI-BLAST. A new generation of protein database search programs. NucleicAcid Res.
- 549 1997; 25(17): 3389–3402. https://doi.org/10.1093/nar/25.17.3389 PMID: 9254694.
- 550 29. Khakabimamaghani S, Najafi A, Ranjbar R, Raam M. GelClust: a software tool for gel
- electrophoresis images analysis and dendrogram generation. Comput Methods Programs
- *Biomed.* 2013; 111(2):512–8. https://doi.org/10.1016/j.cmpb.2013.04.013 PMID: 23727299.
- 553 30. Naylor N.R.; Atun R.; Zhu N.; Kulasabanathan K.; Silva S.; Chatterjee A.; et al. Estimating
- the burden of antimicrobial resistance: a systematic literature review. *Antimicrob. Resist.*
- 555 Infect. Control. 2018; 7(58):1-17. https://doi.org/10.1186/s13756-018-0336-y PMID:
- **29713465**.
- 31. Maslikowska J.A.; Walker S.A.; Elligsen M.; Mittmann N.; Palmay L.; Daneman N.; et al.
- Impact of infection with extended-spectrum beta-lactamase-producing *Escherichia coli* or
- *Klebsiella* species on outcome and hospitalization costs. *J. Hosp. Infect.* 2016; 92, 33–41.
- 32. Ruppé É.; Woerther P.L.; Barbier F. Mechanisms of antimicrobial resistance in Gram-
- negative bacilli. Ann Intensive Care. 2015; 5:21:1-15. https://doi.org/10.1186/s13613-015-
- 562 0061-0 PMID: 26261001.
- 563 33. Pál T.; Butt A.B.; Ghazawi A.; Jens Thomsen J.; Rizvi T.A.; Sonnevend A. Early Years of
- Carbapenem-Resistant Enterobacterales Epidemic in Abu Dhabi. *Antibiotics*. Antibiotics
- 565 2022; 11:1435:1-11. https://doi.org/10.3390/antibiotics11101435 PMID: 36290093.

- 34. Mahamat O.O.; Lounnas M.; Hide M.; Dumont Y.; Tidjani A.; Kamougam K.; et al. High
- prevalence and characterization of extended-spectrum β-lactamase producing
- Enterobacteriaceae in Chadian hospitals. BMC Infect Dis. 2019; 19(1):205:1-7.
- https://doi.org/10.1186/s12879-019-3838-1 PMID: 30819135.
- 570 35. U.A.E Ministry of Health and Prevention. United Arab Emirates Surveillance of
- 571 Antimicrobial Resistance Annual Report. 2022.
- https://mohap.gov.ae/assets/f5a5705/National%20AMR%20Surveillance%20Report%20202
- 573 2%20MOHAP 638205230312192483.pdf.aspx
- 574 36. Al-Agamy M.H.; Aljallal A.; Radwan H.H.; and Shibl A.M. Characterization of
- carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in carbapenem-
- insensitive Escherichia coli and Klebsiella pneumoniae in Riyadh hospitals. J. Infect. Public
- 577 *Health.* 2018; 11, 64–68. https://doi.org/10.1016/j.jiph.2017.03.010 PMID: 28462854.
- 578 37. Kabrah A. Extended-spectrum beta-lactamase and carbapenem-resistant gram-negative
- pathogens in makkah, Saudi Arabia. Ethiop J. Health Sci. 2022; 32 (6): 1221-1230.
- 580 https://doi.org/10.4314/ejhs.v32i6.20 PMID: 36475249.
- 38. Ardati K.O.; Chacko S.T.; Jagtap A.; and Jacob S. Prevalence of bacterial pathogens and
- antimicrobial susceptibility pattern in Bahrain tertiary care hospital. J. Bahrain Med. Soc.
- 583 2019; 31: 5–16. https://doi.org/10.26715/jbms.31 06032019
- 584 39. Shaaban O.A.; Mahmoud N.A.; Zeidan A.A.; Kumar N.; Finan A.C. Prevalence and resistance
- patterns of pediatric urinary tract infections in Bahrain. Cureus. 2021; 13: e20859:1-10.
- 586 https://doi.org/10.7759/cureus.20859 PMID: 35141098.

- 587 40. Mohammed D.; Isa H.M.; Ali, M.F. Microbial etiology and antibiotic resistance patterns of
- urinary tract pathogens in hospitalized infants in Bahrain: a tertiary care center experience.
- 589 *Cureus.* 2022; 16:14(9):e29236. https://doi.org/10.7759/cureus.29236 PMID: 36277545.
- 41. Alfaresi M.; Kim Sing G.; Senok A. First report of *bla<sub>CTX-M-28</sub>* in Enterobacteriaceae isolates in
- the United Arab Emirates. *J. Pathog.* 2018; 1304793. https://doi.org/10.1155/2018/1304793
- 592 PMID: 29593911.
- 593 42. Karlowsky J.A.; Lob S.H.; Deryke C.A.; Siddiqui F.; Young K.; Motyl M.R.; et al. Prevalence
- of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates
- collected by the SMART global surveillance program from 2015 to 2019. *Int. J. Antimicrob*.
- 596 Agents. 2022; 59, 106535. https://doi.org/10.1016/j.ijantimicag.2022.106535 PMID:
- 597 <u>29593911</u>.
- 598 43. Perez-Lopez A.; Sundararaju S.; Al-Mana H.; Tsui K.M.; Hasan MR.; Suleiman M.; et al.
- Molecular characterization of extended-spectrum beta-Lactamase-Producing *Escherichia coli*
- and Klebsiella pneumoniae among the pediatric population in Qatar. Front. Microbiol. 2020;
- 601 11: 581711. https://doi.org/10.3389/fmicb.2020.581711 PMID: 33262745.
- 602 44. Al-Tawfiq J.A.; Rabaan A.A.; Saunar J.V.; Bazzi A.M. Antimicrobial resistance of gram-
- negative bacteria: a six-year longitudinal study in a hospital in Saudi Arabia. J. Infect. Public
- 604 *Health.* 2020; 13:737–745. <a href="https://doi.org/10.1016/j.jiph.2020.01.004">https://doi.org/10.1016/j.jiph.2020.01.004</a> PMID: <a href="mailto:32008927">32008927</a>.
- 45. Ibrahim M.E.; Algak T.B.; Abbas M.; Elamin B.K. Emergence of bla<sub>TEM</sub>, bla<sub>CTX-M</sub>, bla<sub>SHV</sub> and
- $bla_{OXA}$  genes in multidrug-resistant *Enterobacteriaceae* and *Acinetobacter baumannii* in Saudi
- Arabia. Exp. Ther. Med. 2021; 22(6):1450. https://doi.org/10.3892/etm.2021.10885.1450
- 608 PMID: 34721692.

- 46. Azim N.S.A.; Nofal M.Y.; Alharbi M.A.; Al-Zaban M.I.; Somily A.M. Molecular-diversity,
- prevalence and antibiotic susceptibility of pathogenic Klebsiella pneumoniae under Saudi
- 611 condition. Pak J. Biol. Sci. 2019; 22(4):174–179. https://doi.org/10.3923/pjbs.2019.174.179
- 612 PMID: 31930818.
- 613 47. Dash N.R.; Albataineh M.T.; Alhourani N.; Khoudeir A.M.; Ghanim M.; Wasim M.; et al.
- 614 Community-acquired urinary tract infections due to extended-spectrum b-lactamase-producing
- organisms in United Arab Emirates. Travel Med. Infect. Dis. 2018; 22:46–50.
- https://doi.org/10.1016/j.tmaid.2018.01.007 PMID: 29409967.
- 48. Al-Sweih N.; Jamal W.; Mokaddas E.; Habashy N.; Kurdi A.; Mohamed N. Evaluation of the
- in vitro activity of ceftaroline, ceftazidime/avibactam and comparator antimicrobial agents
- against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012-19. JAC
- 620 Antimicrob. Resist. 2021; 3(4):1-10. https://doi.org/10.1093/jacamr/dlab159 PMID:
- 621 36479234.
- 49. Aldrazi F.A.; Rabaan A.A.; Alsuliman S.A.; Aldrazi H.A.; Alabdalslam M.J.; Alsadiq S.A.; et
- al. ESBL expression and antibiotic resistance patterns in a hospital in Saudi Arabia: do
- healthcare staff have the whole picture? J. Infect. Public Health. 2020; 13(5): 759–766.
- https://doi.org/10.1016/j.jiph.2019.12.001 PMID: 31901487.
- 626 50. Jalal N.A.; Al-Ghamdi A.M.; Momenah A.M.; Ashgar S.S.; Bantun F.; Bahwerth F.S.; et al.
- Prevalence and antibiogram pattern of klebsiella pneumoniae in a tertiary care hospital in
- makkah, Saudi Arabia: an 11-year experience. Antibiotics (Basel) 2023; 12(1):164.
- https://doi.org/10.3390/antibiotics12010164 PMID: 36671365.
- 630 51. Rather J.I.; Mohiuddin Z.; Syed F.N.; Haris M.; Nabi M.; Farooq A.; et al. Gram-Negative
- Extended Spectrum Beta-Lactamase Producing Bacteria Prevalence in Jouf Region Tertiary

- Care Hospital, Saudi Arabia. J Pure Appl Microbiol. 2021; 15(1):421-427.
- 633 https://doi.org/10.22207/JPAM.15.1.39.
- 634 52. Mo L.; Wang J.; Qian J.; Peng M. Antibiotic Sensitivity of Proteus mirabilis Urinary Tract
- Infection in Patients with Urinary Calculi. Int J Clin Pract. 2022; 2022: 7273627.
- https://doi.org/10.1155/2022/7273627 PMID: 36628152.
- 637 53. Omer T.H.S.; Mustafa S.A.M.; Mohamed S.O.O. Extended Spectrum β-Lactamase-Mediated
- Resistance and Antibiogram of *Pseudomonas aeruginosa* Isolates from Patients Attending
- Two Public Hospitals in Khartoum, Sudan. Int J Microbiol. 2020; 2020: 2313504.
- https://doi.org/10.1155/2020/2313504 PMID: 33163076.
- 641 54. Elhariri M.; Hamza D.; Elhelw R.; Dorgham S.M. Extended-spectrum
- beta-lactamase-producing *Pseudomonas aeruginosa* in camel in Egypt: potential human
- hazard. Ann Clin Microbiol Antimicrob. 2017; 16(1):21. https://doi.org/10.1186/s12941-017-
- 644 0197-x PMID: 28359312.
- 55. Sannathimmappa M.B.; Nambiar V.; Aravindakshan R. Antibiotic Resistance Pattern of
- 646 Acinetobacter baumannii Strains: A Retrospective Study from Oman. Saudi J Med Med Sci.
- 2021; 9(3):254-60. https://doi.org/10.4103/sjmms.sjmms 855 20 PMID: 34667473.
- 56. Tashkan B.B.; Niakan M.; Khaledi M.; Afkhami H.; Sameni F.; Shahriar Bakhti S.; et al.
- Antibiotic resistance assessment of *Acinetobacter baumannii* isolates from Tehran hospitals
- due to the presence of efflux pumps encoding genes (adeA and adeS genes) by molecular
- method. BMC Res Notes. 2020; 13(1):543. https://doi.org/10.1186/s13104-020-05387-6
- 652 PMID: 33213526.

- 653 57. Paterson D.L.; Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin
- 654 *Microbiol Rev.* 2005; 18(4):657–86. https://doi.org/10.1128/CMR.18.4.657-686.2005 PMID:
- 655 16223952.
- 656 58. Naira A.; Majeed B.; Begum H.; Rukshana N.; Rahamathullah N.; Khan Z.A. Prevalence of
- Extended-Spectrum of Beta-Lactamase-producing class a genes in *Escherichia coli* and
- 658 Klebsiella pneumoniae isolated from patients urine samples in United Arab Emirates.
- 659 International Journal of Health Sciences. 2022; 6(S5):4577–4587.
- https://doi.org/10.53730/ijhs.v6nS5.10081.
- 59. Eltai N.O.; Al-Thani A.A.; Al-Ansari K.; Deshmukh A.S.; Wehedy E.; Al-Hadidi S.H.; et al.
- Molecular characterization of extended spectrum β-lactamases enterobacteriaceae causing
- lower urinary tract infection among pediatric population. *Antimicrob Resist Infect Control.*
- 2018; 7:90. https://doi.org/10.1186/s13756-018-0381-6 PMID: 30069306.
- 665 60. Azab K.S.M.; Abdel-Rahman M.A.; El-Sheikh H.H.; Azab E.; Gobouri A.A.; Farag M.M.S.;
- Distribution of extended-spectrum beta-lactamase (ESBL)-encoding genes among multidrug-
- resistant gram-negative pathogens collected from three different countries. *Antibiotics (Basel)*.
- 2021; 10(3): 247. https://doi.org/10.3390/antibiotics10030247 PMID: 3380141810.
- 669 61. Pishtiwan A.H.; Khalil Mustafa Khadija K.M. Prevalence of blaTEM, blaSHV, and blaCTX-
- 670 M Genes among ESBL-Producing Klebsiella pneumoniae and Escherichia coli Isolated from
- Thalassemia Patients in Erbil, Iraq. Mediterr J Hematol Infect Dis. 2019; 11(1):e2019041.
- https://doi.org/10.4084/MJHID.2019.041 PMID: 31308917.
- 62. Bajpai T.; Pandey M.; Varma M.; Bhatambare G.S. Prevalence of TEM, SHV, and CTX-M
- Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. *Avicenna J Med.* 2017;
- 675 7(1):12-6. https://doi.org/10.4103/2231-0770.197508 PMID: 28182026.

- 676 63. Zaki M.; El-Halaby H.; Elmansoury E.; Zeid M.; Khaled K.; Nomir M. Genetic Study of
- Extended Spectrum Beta-Lactamase and Carbapenemase Producing *Escherichia coli* Causing
- Sepsis among Egyptian Children. The Open Microbiology Journal 2019; 13: 128-137.
- 679 https://doi.org/10.2174/1874285801913010128. PID: TOMICROJ-13-128.
- 680 64. Al-Rashed N.; Bindayna K.M.; Mohammad Shahid M.; Saeed NK.; Darwish A.; Joji R.M; et
- al. Prevalence of Carbapenemases in Carbapenem-Resistant *Acinetobacter baumannii* Isolates
- from the Kingdom of Bahrain. Antibiotics. 2023; 12:1198.
- https://doi.org/10.3390/antibiotics12071198 PMID: 37508294.
- 684 65. Zaman T.U.; Aldrees M; Al Johani S.M.; Alrodayyan M; Aldughashem F.A.; Balkhy H.H.
- Multi-drug carbapenem- resistant *Klebsiella pneumoniae* infection carrying the OXA-48
- gene and showing variations in outer membrane protein 36 causing an outbreak in a tertiary
- care hospital in Riyadh, Saudi Arabia. *International Journal of Infectious Diseases*. 2014;
- 28:186–192. https://doi.org/10.1016/j.ijid.2014.05.021 PMID: 25245001
- 689 66. Memish Z.A.; Assiri A.; Almasri M.; Roshdy H.; Hathout H.; Kaase M.; et al. Molecular
- characterization of carbapenemase production among gram-negative bacteria in Saudi
- 691 Arabia. *Microbial Drug Resistance*. 2015; 21(3):307–314.
- https://doi.org/10.1089/mdr.2014.0121 PMID: 25569024
- 693 67. Nordmann P.; Poirel L.; Carrer A.; Toleman M.A.; Walsh T.R. How to detect NDM-1
- 694 producers. Journal of clinical microbiology. 2011; 49(2):718–721.
- 695 https://doi.org/10.1128/JCM.01773-10 PMID: 21123531.
- 68. Kamel K.A.; El-Tayeb W.N.; El-Ansary M.R.; Mansour M.T.; Aboshanab K.M. Phenotypic
- screening and molecular characterization of carbapenemase-producing Gram-negative bacilli
- recovered from febrile neutropenic pediatric cancer patients in Egypt. *PLoS One.* 2018;

- 699 13(8):0202119. https://doi.org/10.1371/journal.pone.0202119 PMID: 30157188.
- 700 69. Moglad E.; Alanazi N.; Altayb H.N.; Genomic Study of Chromosomally and Plasmid-
- 701 Mediated Multidrug Resistance and Virulence Determinants in Klebsiella Pneumoniae Isolates
- Obtained from a Tertiary Hospital in Al-Kharj, KSA. *Antibiotics (Basel)*. 2022; 11(11):1564.
- 703 https://doi.org/10.3390/antibiotics11111564 PMID: 36358219.
- 70. Badger-Emeka L.I.; Kausar N.; Estrella E.; Angeles G.B. A three-year look at the phylogenetic
- profile, antimicrobial resistance, and associated virulence genes of uropathogenic *Escherichia*
- 706 coli. Pathogens. 2022; 11(6):631. https://doi.org/10.3390/pathogens11060631 PMID:
- 707 35745485.
- 708 71. Sid-Ahmed M.A.; Bansal D.; Acharya A.; Elmi A.A.; Hamid J.M.; Sid Ahmed A.M.; et al.
- Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-
- 710 lactamase-producing Enterobacteriaceae from intensive care units at Hamad Medical
- 711 Corporation, Qatar. Antimicrob. Resist. Infect. Control 2016; 5:4.
- 712 https://doi.org/10.1186/s13756-016-0103-x PMID: 26865975.
- 713 72. Elbadawi H.S.; Elhag K.M.; Mahgoub E.; Altayb H.N.; Ntoumi F.; et al. Detection and
- 714 characterization of carbapenem resistant Gram-negative bacilli isolates recovered from
- hospitalized patients at Soba University Hospital, Sudan. *BMC Microbiol*. 2021; 21(1):136.
- 716 https://doi.org/10.1186/s12866-021-02133-1 PMID: 33947325.




Fig 1. Detection of blaCTX-M, blaTEM, blaSHV, blaIMP & blaNDM




Fig 2. No. of Gram -ve and gram +ve bacteria isolated from vario




Fig 3. Total no. of E. coli, K. pneumoniae, P. aeruginosa, P. mirabil




Fig 4. Heatmap of antibiotic sensitivity pattern




Fig 5. Heatmap of frequency of class A ESBL and class B carbape

Fig 6. Frequency of detection of class A ESBL and class B & D car




Fig 7. Cladogram of the phylogenetic tree of the class